KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
183 hedge funds and large institutions have $1.39B invested in KalVista Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 63 increasing their positions, 45 reducing their positions, and 16 closing their positions.
156% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 16
84% more call options, than puts
Call options by funds: $39.1M | Put options by funds: $21.2M
80% more funds holding in top 10
Funds holding in top 10: 5 → 9 (+4)
40% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 45
29% more capital invested
Capital invested by funds: $1.08B → $1.39B (+$313M)
14% more funds holding
Funds holding: 161 → 183 (+22)
2.77% more ownership
Funds ownership: 132.43% → 135.2% (+2.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$9.09M |
| 2 |
SSC
Spruce Street Capital
New York
|
+$8.22M |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$7.24M |
| 4 |
AC
Armistice Capital
New York
|
+$7.03M |
| 5 |
CCM
Catalio Capital Management
New York
|
+$6.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$15.9M |
| 2 |
Schroder Investment Management Group
London,
United Kingdom
|
-$10.7M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$6.63M |
| 4 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
-$5.68M |
| 5 |
O
OrbiMed
New York
|
-$4.64M |
KALV Hedge Fund Activity: Q1 2026 in Review
183 of the 8,133 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q1 2026, worth a combined $1.39B — up 29% from $1.08B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new KALV positions and 16 closed out — a net gain of 25 holders — while 63 added to existing stakes and 45 trimmed.
The largest buyer was Driehaus Capital Management, opening a new position worth an estimated $9.09M. The largest seller was Millennium Management, cutting an estimated $15.9M.
- 183 institutional investors held KalVista Pharmaceuticals (KALV) as of Q1 2026, up from 161 in Q4 2025.
- Funds reported $1.39B of KalVista Pharmaceuticals stock for Q1 2026, up 29% quarter-over-quarter.
- 41 funds opened new KalVista Pharmaceuticals positions in Q1 2026 and 16 closed out, a net change of +25 holders.
- The largest KalVista Pharmaceuticals buyer in Q1 2026 was Driehaus Capital Management, an estimated $9.09M added.
- The largest KalVista Pharmaceuticals seller in Q1 2026 was Millennium Management, an estimated $15.9M sold.
Based on aggregated 13F filings for Q1 2026.